Enzymes for Multi-Drug Resistance Research
Review Article:
Cytochrome P450 and Related Enzymes
The hepatic microsomal cytochrome P450s are members of a superfamily of monoxygenases that catalyze the oxidative metabolism of xenobiotics, the initial step in the biotransformation and elimination of a wide variety of drugs and environmental pollutants. P450s are located primarily in the endoplasmic reticulum of liver tissue. Until now the difficulty of isolating and reconstituting native enzymes from human tissue has hampered their use for studies with well-defined in vitro drug metabolism systems.
Applications
- Isozyme identification
- Determination of kinetic parameters for substrates and inhibitors
- Isolation and synthesis of rare and novel metabolites
- Stereo- and/or regio-specific hydroxylation reactions
- High-throughput in vitro screening
Hepatic microsomal cytochrome P450, human recombinant, was expressed in over producing E. coli.
| Product Number |
Product Description |
| C 3735 |
Cytochrome P450 1A1 Isozyme, microsomes, human |
| C 7803 |
Cytochrome P450 1A2 Isozyme, human |
| C 6107 |
Cytochrome P450 1A2 Isozyme, microsomes, human |
| C 3860 |
Cytochrome P450 1B1 Isozyme, microsomes, human |
| C 3985 |
Cytochrome P450 2A6 Isozyme, microsomes, human |
| C 4735 |
Cytochrome P450 2A6 Isozyme, microsomes, human, with cytochrome with b5 |
| C 7552 |
Cytochrome P450 2B4, from rabbit liver |
| C 3360 |
Cytochrome P450 2B6 Isozyme, microsomes, human |
| C 4860 |
Cytochrome P450 2B6 Isozyme, microsomes, human with cytochrome with b5 |
| C 4110 |
Cytochrome P450 2C8 Isozyme, microsomes, human |
| C 3485 |
Cytochrome P450 2C8 Isozyme, microsomes, human, with cytochrome with b5 |
| C 7817 |
Cytochrome P450 2C9 Isozyme, human |
| C 5107 |
Cytochrome P450 2C9 Isozyme, microsomes, human |
| C 4235 |
Cytochrome P450 2C92 Isozyme, microsomes, human |
| C 4360 |
Cytochrome P450 2C93 Isozyme, microsomes, human |
| C 4485 |
Cytochrome P450 2C18 Isozyme, microsomes, human |
| C 5607 |
Cytochrome P450 2C19 Isozyme, human |
| C 4857 |
Cytochrome P450 2C19 Isozyme, microsomes, human |
| C 9195 |
Cytochrome P450 2D6 Isozyme, human |
| C 5232 |
Cytochrome P450 2D6 Isozyme, microsomes, human |
| C 9573 |
Cytochrome P450 2E1 Isozyme, human |
| C 4982 |
Cytochrome P450 3A4 Isozyme, microsomes, human |
| C 3831 |
Cytochrome P450 3A4 Isozyme, human |
| C 6232 |
Cytochrome P450 3A5 Isozyme, microsomes, human |
| C |
Cytochrome P450 3A7 Isozyme, microsomes, human, with cytochrome b5 |
| C 4610 |
Cytochrome P450 4A11 Isozyme, microsomes, human |
| C 4985 |
Cytochrome P450 4F2 Isozyme, microsomes, human, with cytochrome b5 |
| C 5110 |
Cytochrome P450 4F3A Isozyme, microsomes, human, with cytochrome b5 |
| C 5235 |
Cytochrome P450 4F3B Isozyme, microsomes, human, with cytochrome b5 |
| C 5357 |
Cytochrome P450 Isozyme control, microsomes, human |
Hepatic microsomal cytochrome P450 2B4 from rabbit liver was induced with phenobarbital.
| Product Number |
Product Description |
| C 7552 |
Cytochrome P450 Isozyme 2B4 |
back to top
Cytochrome-P450 reductase transfers electrons from NADPH to the various isoforms of cytochrome P450. It is a membrane-bound flavoprotein containing one mole each of FAD and FMN. Sigma offers two product options. Sigma's human Cytochrome-P450 reductase is produced from insect cells infected with baculovirus containing the cDNA for human P450 reductase.Sigma's nonrecombinant version is isolated from rabbit liver induced with phenobarbital.
| Product Number |
Product Description |
| N 5516 |
NADPH-P450 Reductase, Human Recombinant |
| C 4839 |
NADPH-P450 Reductase, Rabbit |
back to top
Cytochrome b5 is a membrane-bound hemoprotein that enhances the catalytic efficiency of some P450 isoforms. Sigma's human cytochrome b5 is overexpressed in E. coli and purified to homogeneity.
| Product Number |
Product Description |
| C 1427 |
Cytochrome b5 |
back to top
Five allelic variants of sulfotransferase enzymes are offered for sudies involving drug disposition research. Sigma's highly active cytosolic extracts are produced from insect cells that are infected with a baculovirus containing a cDNA for human sulfotransferases.
| Product Number |
Product Description |
| S 1677 |
Sulfotransferase 1A12 Isozyme, human, cytosol extract |
| S 8928 |
Sulfotransferase 1A21 Isozyme, human, cytosol extract |
| S 6054 |
Sulfotransferase 1A3 Isozyme, human, cytosol extract |
| S 8309 |
Sulfotransferase 1E Isozyme, human, cytosol extract |
| S 8434 |
Sulfotransferase 2A1 Isozyme, human, cytosol extract |
| S 7188 |
Sulfotransferase SF9 wild type control, human, cytosol extract |
back to top
Glutathione transferases (GSTs) catalyze the formation of thioether conjugates between glutathione and xenobiotic compounds. Their major biological function is believed to be defense against electrophilic chemical species, many of which are formed by cellular oxidative reactions catalyzed by cytochrome P450 and other oxidases. Sigma's recombinant human GSTs are over-expressed in E. coli and purified by affinity chromatography.
| Product Number |
Product Description |
| G 5524 |
Glutathione S-Transferase A1-1 Isozyme, human |
| G 4151 |
Glutathione S-Transferase M1-1 Isozyme, human |
| G 1902 |
Glutathione S-Transferase P1-1 Isozyme, human |
| G 4385 |
Glutathione S-Transferase from bovine liver |
| G 6511 |
Glutathione S-Transferase from equine liver |
| G 6636 |
Glutathione S-Transferase from porcine liver |
| G 5663 |
Glutathione S-Transferase from Schistosoma japonicum |
back to top
Examining the glucuronidation reactions catalyzed by the human UDP-glycosyltransferase (UGT) family of enzymes is essential when investigating the metabolic fate of any new drug, therapeutic agent, or chemical present in the environment. Sigma's human UDP-glycosyltransferases are produced as a microsomal fractions of Sf-9 insect cells infected with a baculovirus strain containing cDNA for a specific human UGT.
| Product Number |
Product Description |
| U 7254 |
UDP-Glucuronosyltransferase 1A1 Isozyme, microsomes, human |
| U 8379 |
UDP-Glucuronosyltransferase 1A3 Isozyme, microsomes, human |
| U 7379 |
UDP-Glucuronosyltransferase 1A6 Isozyme, microsomes, human |
| U 7504 |
UDP-Glucuronosyltransferase 1A7 Isozyme, microsomes, human |
| U 7629 |
UDP-Glucuronosyltransferase 1A10 Isozyme, microsomes, human |
| U 8504 |
UDP-Glucuronosyltransferase 2B7 Isozyme, microsomes, human |
| U 8007 |
UDP-Glucuronosyltransferase SF9 Wild type control, microsomes |
Cytochrome P450 Fluorescent Detection Kits. With these kits, you can extract samples and assay them for either cytochrome P450 2B4 or P450 1A1/2 activity.Kits contain sufficient reagents for extraction of up to 7.5 g of tissue and up to 50 assays. Ethoxyresorufin and methoxyresorufin are supplied as substrates.
| Product Number |
Product Description |
| Cyto-1A |
Cytochrome P450 1A1/2 Activity Kit |
| Cyto-2B |
Cytochrome P450 2B Activity Kit |
back to top
Substrates
| Product Number |
Product Description |
Function |
| A 6636 |
Aflatoxin B1 |
CYP1A2, CYP2A6, CYP2D6, and CYP3A family substrate |
| A 8423 |
Amiodarone Hydrochloride |
CYP2C8/9 and CYP3A family (minor pathway) inhibitor and substrate; CYP2D6, CYP3A family, CYP2D6, CYP2A6, CYP2B6 desethyl-form inhibitor |
| B 5057 |
7-Benzyloxy-4-Trifluoromethylcoumarin |
P450 substrate |
| B 5182 |
7-Benzyloxyquinoline (BQ) |
P450 substrate |
| B 1532 |
7-Benzyloxyresorufin |
P450 substrate |
| C 8138 |
Chlorpromazine Hydrochloride |
CYP1A1, CYP2D6, Gluc1A3, Gluc1A4 substrate |
| C 4397 |
Chlorzoxazone |
CYP1A2, CYP2E1, and CYP3A family substrate |
| C 6305 |
Clozapine |
CYP1A2, CYP2C19, CYP2D6, CYP2A6, CYP3A family, Gluc1A4, Gluc1A3, Gluc1A4 (desmethoxy metabolite only) substrate |
| D 1306 |
Debrisoquine Sulfate |
P450, CYP2D6 Substrate |
| D 1756 |
Dexamethasone |
CYP2A6, CYP3A and Gluc1 family substrate |
| D 2531 |
Dextromethorphan Hydrobromide |
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A family substrate |
| D 6899 |
Diclofenac Sodium |
CYP8/9 inhibitor and substrate; CYP2C19, CYP2B6, Gluc2B7, Gluc1A3, Gluc1A9, CYP3A family substrate; Gluc2B9 and Gluc2B7 inducer |
| D 5878 |
Digitoxin |
CYP3A family substrate |
| D 6003 |
Digoxin |
CYP3A family substrate (minor pathway) |
| D 2521 |
Diltiazem Hydrochloride |
CYP2C8, CYP2C9, CYP3A family substrate |
| D 4505 |
5,5-Diphenylhydantoin Sodium (Phenytoin) |
CYP2C8, CYP2C9, CYP2C19, Gluc2B15 substrate; CYP2B6, Gluc1, Gluc2, and CYP3A family inducer |
| D 4035 |
Doxorubicine Hydrochloride with extender and preservative |
CYP2D6 and CYP3A family inhibitor and substrate |
| E 3763 |
Ethoxyresorufin |
P450 substrate |
| E 1383 |
Etopsoside |
Cell cycle inhibitor; CYP3A family substrate; CYP1A2 and CYP2E1 (minor pathway) substrate |
| F 9261 |
Flunitrazepam |
CYP2C19 substrate; CYP3A inhibitor or substrate; Gluc2B7 inducer |
| F-132 |
Fluoxetine Hydrochloride |
CYP2C8/9, CYP2D6, CYP3A family substrate and inhibitor; CYP1A2 and CYP2B6 inhibitor (includes active metabolites) |
| G 9659 |
GBR-12935 Dihydrochloride |
P450 substrate |
| G 4251 |
Glutathione Free Acid Reduced |
CYP2E1 substrate, known to be transported by MRP |
| H 1512 |
Haloperidol |
CYP2D6 inhibitor and substrate; UGT and CYP3A family substrate |
| H 4001 |
Hydrocortisone |
CYP3A family inducer and substrate |
| I 7378 |
Indomethacin |
CYP2C19 inducer and substrate; CYP2C8/9 substrate; possible Gluc2B7 inducer |
| I 3377 |
Isonicotinic Acid Hydrazine Free Base (Isoniazid) |
CYP2C19 substrate |
| K 1003 |
Ketoconazole |
CYP3A family inhibitor and substrate; CYP1A2, CYP2C19, and CYP2A6 inhibitor |
| L 1026 |
Lidocaine |
CYP1A2 inhibitor and substrate; CYP2B6 and CYP3A family substrate |
| M 8189 |
7-Methoxy-4-Trifluoromethylcourmarin |
P450 substrate |
| M 1544 |
Methoxyresorufin |
P450 substrate |
| M 2147 |
Mevinolin (Lovastatin) |
CYP2C8/9 inhibitor; CYP2C8/9 and CYP3A family substrate (metabolite) |
| N 7510 |
Nicardipine Hydrochloride |
CYP3A family substrate and inhibitor; CYP2C8/9, CYP2C19, CYP2D6 inhibitor |
| N 7634 |
Nifedipine |
CYP3A family substrate and inhibitor; CYP2C8/9 inhibitor |
| N-144 |
Nitrendipine |
CYP3A family substrate |
| O-104 |
Omeprazole |
CYP2C19 and CYP3A family substrate and inhibitor; CYP2C8/9 inhibitor, CYP2C19 substrate (R- form) |
| T 1912 |
Paclitaxel from Taxus Yannanensis |
CYP2C8/9 substrate; CYP3A family inducer and substrate |
| P 0928 |
7-Pentoxyresorufin (O7 Pentylresorufin) |
P450 substrate |
| A 2500 |
Phenacetin (Acetophenetidin) |
P450, CYP1A2, 2C9, 2C19, 2D6 Substrate |
| P 1294 |
1,10-Phenanthroline Monohydrate |
P450 substrate |
| P 5178 |
Phenobarbital Sodium |
CYP2C19 substrate; CYP2C8/9, CYP1A2, CYP2D6, CYP2A6, CYP2B6, CYP3A, Gluc1, Gluc2 family inducer |
| P 8386 |
Phenylbutazone |
CYP2C8/9 inhibitor; CYP3A family inducer |
| P 9391 |
Procainamide Hydrochloride |
CYP2D6 substrate; NAT2-selective substrate |
| P 0130 |
Progesterone |
CYP2C8/9, CYP2C19, CYP3A family substrate; Pgp inhibitor |
| Q 0750 |
Quinidine Hydrochloride |
CYP3A family substrate and inhibitor; CYP2D6 inhibitor; CYP2C8/9 and CYP2E1 substrate |
| R-101 |
Ranitidine Hydrochloride |
CYP1A2, CYP2C19, CYP2D6 substrate; possible Gluc2 inducer; FMO substrate |
| R 0395 |
Rapamycin (Sirolimus) |
CYP3A family substrate |
| T 5648 |
Tamoxifen |
CYP2C8/9, CYP2D6, CYP2E1, CYP3A family substrate |
| T 9652 |
Terfenadine |
CYP3A family substrate; Pgp inhibitor |
| T 1500 |
Testosterone |
CYP2D6 and possible CYP3A family substrate |
| T 0891 |
Tolbutamide |
CYP2C8/9, CYP2C19 substrate |
| P 1761 |
trans-2-Phenylcyclopropylamine Hemisulfate (Tranylcypromine) |
CYP2C19, CYP2E1, CYP2A6 inhibitor; MAO substrate |
| T 6154 |
Trazodone Hydrochloride |
CYP3A family substrate; CYP2D6 substrate (metabolite) |
| T 8516 |
Trifluoroperazine Dihydrochloride |
CYP1A2 (minor pathway) substrate; Gluc1A4 substrate; Pgp inhibitor |
| V 4629 |
(+-)- Verapamil Hydrochloride |
CYP3A family inhibitor and substrate; CYP1A2, CYP2C8/9, CYP2C19 (minor pathway) substrate; Pgp inhibitor |
| V 1377 |
Vinblastine Sulfate |
CYP2D6 inhibitor and substrate; CYP3A family substrate; Pgp substrate |
| V 8879 |
Vincristine Sulfate |
CYP3A family substrate; Pgp inducer |
| A 2250 |
Warfarin |
CYP2C8 and CYP2C9 S-form substrate; 1A2 R-form substrate; R-form may inhibit CYP2C9 |
| C 8138 |
Chlorpromazine Hydrochloride |
CYP1A1, CYP2D6, Gluc1A3, Gluc1A4 substrate |
| C 6305 |
Clozapine |
CYP1A2, CYP2C19, CYP2D6, CYP2A6, CYP3A family, Gluc1A4, Gluc1A3, Gluc1A4 (desmethoxy metabolite only) substrate |
| D 1756 |
Dexamethasone |
CYP2A6, CYP3A and Gluc1 family substrate |
| D 6899 |
Diclofenac Sodium |
CYP8/9 inhibitor and substrate; CYP2C19, CYP2B6, Gluc2B7, Gluc1A3, Gluc1A9, CYP3A family substrate; Gluc2B9 and Gluc2B7 inducer |
| D 4505 |
5,5-Diphenylhydantoin Sodium (Phenytoin) |
CYP2C8, CYP2C9, CYP2C19, Gluc2B15 substrate; CYP2B6, Gluc1, Gluc 2, and CYP3A family inducer |
| T 8516 |
Trifluoroperazine Dihydrochloride |
CYP1A2 substrate (minor pathway); Gluc1A4 substrate; Pgp inhibitor |
back to top
Inhibitors
| Product Number |
Product Description |
Function |
| A 8423 |
Amiodarone Hydrochloride |
CYP2C8/9 and CYP3A family (minor pathway) inhibitor and substrate; CYP2D6, CYP3A family, CYP2D6, CYP2A6, CYP2B6 desethyl-form inhibitor |
| C 4522 |
Cimetidine |
CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A family inhibitor |
| D 6899 |
Diclofenac Sodium |
CYP8/9 inhibitor and substrate; CYP2C19, CYP2B6, Gluc2B7, Gluc1A3, Gluc1A9, CYP3A family substrate; Gluc2B9 and Gluc2B7 inducer |
| D 4035 |
Doxorubicine Hydrochloride with extender and preservative |
CYP2D6 and CYP3A family inhibitor and substrate |
| E 3764 |
Enoxacin |
CYP1A2 and CYP3A family inhibitor |
| E 8875 |
B-Estradiol |
CYP1A2 inhibitor |
| F-132 |
Fluoxetine Hydrochloride |
CYP2C8/9CYP2D6, CYP3A family substrate and inhibitor; CYP1A2 and CYP2B6 inhibitor (includes active metabolites) |
| F 4765 |
Fluphenazine Dihydrochloride |
CYP1A2 and CYP2D6 inhibitor |
| F-124 |
Furafylline |
CYP1A2 inhibitor |
| H 1512 |
Haloperidol |
CYP2D6 inhibitor and substrate; UGT and CYP3A family substrate |
| H 8885 |
Hydroxyzine Dihydrochloride |
CYP2D6 inhibitor |
| K 1003 |
Ketoconazole |
CYP3A family inhibitor and substrate; CYP1A2, CYP2C19, and CYP2A6 inhibitor |
| L 1026 |
Lidocaine |
CYP1A2 inhibitor and substrate; CYP2B6 and CYP3A family substrate |
| M 2147 |
Mevinolin (Lovastatin) |
CYP2C8/9 inhibitor; CYP2C8/9 and CYP3A family substrate (metabolite) |
| N 7510 |
Nicardipine Hydrochloride |
CYP3A family substrate and inhibitor; CYP2C8/9, CYP2C19, CYP2D6 inhibitor |
| N 7634 |
Nifedipine |
CYP3A family substrate and inhibitor; CYP2C8/9 inhibitor |
| O 8757 |
Ofloxacin |
CYP1A2 inhibitor |
| O-104 |
Omeprazole |
CYP2C19 and CYP3A family substrate and inhibitor; CYP2C8/9 inhibitor; CYP2C19 substrate (R- form) |
| P 8761 |
Probenecid |
CYP2C19 and Gluc2 inhibitor |
| P 6273 |
2-Propylpentanoic Acid (Valproic acid) |
P450 inhibitor |
| Q 0750 |
Quinidine Hydrochloride |
CYP3A family substrate and inhibitor; CYP2D6 inhibitor; CYP2C8/9 and CYP2E1 substrate |
| S 0758 |
Sulfaphenazole |
P450 enzyme-selective inhibitor |
| S 9509 |
(-+)-Sulfinpyrazone |
CYP2C8/9 inhibitor; CYP3A family inducer; MDR modulating compound |
| P 1761 |
trans-2-Phenylcyclopropylamine Hemisufate (Tranylcypromine) |
CYP2C19, CYP2E1, CYP2A6 inhibitor; MAO substrate |
| V 4629 |
(+-)- Verapamil Hydrochloride |
CYP3A family inhibitor and substrate; CYP1A2, CYP2C8/9, CYP2C19 (minor pathway) substrate; Pgp inhibitor |
| V 1377 |
Vinblastine Sulfate |
CYP2D6 inhibitor and substrate; CYP3A family substrate; Pgp substrate |
| P 8761 |
Probenecid |
CYP2C19 and Gluc2 inhibitor |
back to top back to Enzyme Explorer back to Post-Translation Modification
|